Greater Supply Chain Prepares for Repercussions

Image Credit: Adobe Stock Images/Somneuk.com Key Takeaways Tariffs could spike drug costs: Proposed 25% tariffs on pharmaceuticals may raise US drug prices by up to 12.9% and cost the industry an estimated $51 billion annually. Supply chain disruption is growing: Pharma and medtech sectors face significant supply chain strain, including delays and pricing spikes, due […]

Continue Reading

Five Critical Challenges in Investigator Site Selection and How Clinical Data Science Can Solve Them; Wegovy Use Up 50% Among US Teens

Five Critical Challenges in Investigator Site Selection and How Clinical Data Science Can Solve Them In a Pharmaceutical Executive feature, Gen Li, founder, CEO, Phesi, outlines five key challenges hindering investigator site selection in clinical trials—including unreliable performance predictions and lack of real-world data—and explains how clinical data science and AI-driven tools can optimize site […]

Continue Reading

Why CX Is a Difference Maker for Pharma

Key Takeaways Exceptional CX significantly boosts engagement with healthcare professionals and consumers, leading to increased prescriptions, better market penetration, and improved health outcomes. Pharma companies are leveraging AI-driven omnichannel platforms to unify customer data, personalize interactions, and meet rising expectations across direct-to-consumer and direct-to-patient models. Unified platforms powered by AI enable pharma companies to deliver […]

Continue Reading

Preparing for the Pharma C-Suite; America’s Vanishing Scientific Research Workforce is a Threat to Public Health

Preparing for the Pharma C-Suite In a Pharmaceutical Executive feature, Aileen Fernandes, Chief Business Officer at Arcellx, reflects on how her early roles at Morgan Stanley and Deloitte Consulting, combined with strategic career decisions and authentic leadership development, prepared her for biotechnology C-suite success and offers MBA students key advice on culture fit, building healthcare […]

Continue Reading

Amplifying Workforce Development

In a video interview with Pharma Commerce, Scott Tillman, Logility’s senior vice president of innovation, addresses the gap between high interest in generative AI (GenAI) and its relatively low adoption in supply chain-specific applications, as highlighted in Logility’s Supply Chain Horizons 2025 Market Report. He identified several key reasons for this disconnect. First, many companies […]

Continue Reading

Temperature-Sensitive Tech: Cold Chain’s Continuous Development

May 28th 2025 Article Tasked with the delivery of two ultra-sensitive gene therapies to Japan – treatments targeting vision loss that required continuous -80°C temperature control and dry ice replenishment throughout an 80-hour transit – Marken activated a customized, precision-driven supply chain strategy. Navigating one of the world’s most complex regulatory landscapes for advanced therapies, […]

Continue Reading

Marken’s Precision Logistics Expedites Delivery of Critical Gene Therapies to Japan

May 28th 2025 Article When a South Korean patient needed a life-changing gene therapy, Marken orchestrated an international distribution strategy under the strictest regulatory and temperature specifications. With precise temperature-control required at -80°C with dry ice, Marken’s teams navigated weekend scheduling, specialized package handling and final-mile complexities to ensure the vital treatment remained on schedule […]

Continue Reading

Marken’s Precision Logistics Accelerate Life-Changing Therapy Delivery to Patient in South Korea

May 28th 2025 Article Tasked with the delivery of two ultra-sensitive gene therapies to Japan – treatments targeting vision loss that required continuous -80°C temperature control and dry ice replenishment throughout an 80-hour transit – Marken activated a customized, precision-driven supply chain strategy. Navigating one of the world’s most complex regulatory landscapes for advanced therapies, […]

Continue Reading

How Recent Executive Orders Impact the Drug Pricing Landscape

In this exclusive PC Podcast interview, Alice Valder Curran, partner at Hogan Lovells, explores: How recent executive orders—both under the Biden and Trump administrations—have reshaped the drug pricing landscape, and the legal challenges or uncertainties they present for pharmaceutical companies What life sciences companies should be doing now to proactively prepare for further executive action on drug […]

Continue Reading

Being Digitally Optimized

In a video interview with Pharma Commerce, Scott Tillman, Logility’s senior vice president of innovation, addresses the gap between high interest in generative AI (GenAI) and its relatively low adoption in supply chain-specific applications, as highlighted in Logility’s Supply Chain Horizons 2025 Market Report. He identified several key reasons for this disconnect. First, many companies […]

Continue Reading

FDA Grants Interchangeability Designation to Hadlima

Image Credit: Adobe Stock Images/PostModernStudio.com Key Takeaways Full interchangeability approved: The FDA has granted full interchangeability to Hadlima for all Humira formulations, allowing pharmacist substitution without prescriber consultation (per state law). Expanded patient access: This designation may significantly reduce out-of-pocket costs and improve access to biologic therapies for patients across multiple chronic conditions. Clinical equivalence […]

Continue Reading

Bridging the GenAI Adoption Gap in Supply Chain

In a video interview with Pharma Commerce, Scott Tillman, Logility’s senior vice president of innovation, addresses the gap between high interest in generative AI (GenAI) and its relatively low adoption in supply chain-specific applications, as highlighted in Logility’s Supply Chain Horizons 2025 Market Report. He identified several key reasons for this disconnect. First, many companies […]

Continue Reading

Mercalis and PharmaCord Officially Merge, Form Valeris

Image Credit: Adobe Stock Images/Feodora.com Main Takeaways The merger of Mercalis and PharmaCord, backed by Permira and Odyssey Investment Partners, forms Valeris—a platform aimed at streamlining how life sciences companies bring therapies to market through integrated patient support, data, and provider engagement tools. Valeris intends to transform the commercialization process by improving patient access, reducing […]

Continue Reading

Why It’s Time to Upgrade, and What’s at Stake

The pharmaceutical industry stands at the threshold of a long-overdue transformation in how serialization is approached, implemented, and managed. For more than a decade, serialization has largely been driven by compliance, delivering solutions that meet regulatory requirements but offer limited value beyond the legal minimum. Today, however, the world of pharmaceutical serialization is poised for […]

Continue Reading

A Strategic Imperative for Biopharma Commercial Success; Advocate for Change to Address Pharmacy Burnout

Navigating the Payer-Health System Nexus: A Strategic Imperative for Biopharma Commercial Success Biopharma companies must adopt integrated strategies that engage both payers and health systems—each now powerful, parallel decision-makers—to overcome hidden barriers like “shadow formularies” and ensure successful therapeutic adoption in today’s vertically integrated healthcare landscape, according to a feature in Pharmaceutical Executive. Advocate for […]

Continue Reading

How the Rise of Personalized Medicine Impacts Life Sciences’ Logistics

Key Takeaways Personalized medicine demands precision logistics, with strict temperature control, real-time tracking, and regulatory compliance essential to ensure safe and timely delivery of patient-specific therapies. Gaps in last-mile delivery and third-party training pose serious risks, especially when handling temperature-sensitive, irreplaceable treatments for critically ill patients. Advanced technologies like predictive analytics and smart packaging are […]

Continue Reading

Balancing Benefits, Risks, and Public Perception with HPV Vaccinations; Pfizer-Backed CellCentric Secures $120M for Further Myeloma Trials

HPV Vaccine: Balancing Benefits, Risks, and Public Perception Despite ongoing lawsuits and public concerns about serious adverse events, current evidence supports the safety and effectiveness of the human papillomavirus vaccine in preventing a wide range of cancers, underscoring the need for continued public health advocacy and open patient-provider communication. Pfizer-backed CellCentric secures $120M for further […]

Continue Reading

A Balancing Act

In a video interview with Pharma Commerce, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, describes how his company’s 15th annual Deloitte report on the return on investment (ROI) in pharmaceutical R&D reveals a continued upward trend, with a projected ROI of 5.9% for 2024. This marks a notable reversal from the consistent decline seen […]

Continue Reading

The Road to Simpler and Better Clinical Trials; FDA Outlines Stricter Covid Vaccine Booster Standards for Healthy People

Less is More in Clinical Data: The Road to Simpler and Better Trials In an article for Applied Clinical Trials, Drew Garty, chief technology officer, Veeva, emphasizes that simplifying clinical trial data management through pragmatic strategies—like endpoint-driven design, risk-based approaches, and smart automation—can reduce waste, improve site and patient experiences, and lay the groundwork for […]

Continue Reading

Noom to Sell Microdoses of Wegovy

Image Credit: Adobe Stock Images/PeterHansen.com Key Takeaways Noom is now offering its own compounded version of semaglutide—an active ingredient in Wegovy and Ozempic—through its telehealth marketplace. The FDA has ended the semaglutide shortage and set a May 22 deadline for compounders to cease production. Noom argues for a “personalized” exception, but it’s unclear how the […]

Continue Reading

The GLP-1 Effect

In a video interview with Pharma Commerce, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, describes how his company’s 15th annual Deloitte report on the return on investment (ROI) in pharmaceutical R&D reveals a continued upward trend, with a projected ROI of 5.9% for 2024. This marks a notable reversal from the consistent decline seen […]

Continue Reading

Keeping Drug Supplies Available Means Pharmaceutical Organizations Must Move in Real-Time

Credit: Production Perig | stock.adobe.com Key Takeaways Embrace Real-Time Data for Proactive Supply Chain Management. Advanced manufacturing and real-time analytics help pharmaceutical companies predict and prevent drug shortages. Just like in retail, real-time demand tracking and inventory optimization ensure essential medications are available when needed. Leverage Automation and AI for Resilience and Efficiency. Automated systems […]

Continue Reading

The Role of AI in Solving Clinical Trial Diversity and Access Challenges; FDA Advisors Unanimously Snub Pfizer’s Talzenna in Broader Prostate Cancer Population

The Role of AI in Solving Clinical Trial Diversity and Access Challenges In an interview with Applied Clinical Trials, Michel van Harten, MD, CEO of myTomorrows, explained how AI can help address clinical trial diversity and access challenges by reducing physician workload through treatment matching, simplifying patient education, and breaking down logistical and informational barriers […]

Continue Reading

Bridging Innovation and Trust with Artificial Intelligence; AstraZeneca Partners with Aptar on Kidney Disease-Detecting AI

Bridging Innovation and Trust with Artificial Intelligence In a recent interview with Applied Clinical Trials, Michel van Harten, MD, CEO of myTomorrows, discussed how AI is transforming clinical trials by reducing costs, accelerating timelines, and enhancing patient inclusion—while emphasizing the need for data quality, transparency, and trust to ensure responsible implementation. AZ partners with Aptar […]

Continue Reading

An Exploration of Compounding Practices

Main Takeaways 503B outsourcing facilities must comply with various FDA regulations, including current good manufacturing practices (cGMP), registration, labeling, and adverse-event reporting requirements, which distinguish them from 503A pharmacies and enable them to mass-produce and distribute compounded drugs for office use without patient-specific prescriptions. The FDA’s increased oversight has raised quality and safety standards in […]

Continue Reading

FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research

Image Credit: © JHVEPhoto – stock.adobe.com Key takeaways Placebo-controlled trials now required for low-risk groups: FDA will require placebo-controlled trials for COVID-19 vaccines in low-risk populations before granting full approval—adding complexity to trial design, ethics reviews, and recruitment. New focus on clinical outcomes & longer follow-up: Trials must now measure symptomatic COVID-19 as the primary […]

Continue Reading

Decreasing Clinical Development Timelines

In a video interview with Pharma Commerce, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, describes how his company’s 15th annual Deloitte report on the return on investment (ROI) in pharmaceutical R&D reveals a continued upward trend, with a projected ROI of 5.9% for 2024. This marks a notable reversal from the consistent decline seen […]

Continue Reading

How the Loss of Subsidized Drug Coverage Could Impact Mortality

Image Credit: Adobe Stock Images/Weerasak.com The Low-Income Subsidy, or “Extra Help,” significantly reduces prescription drug costs for 14 million Medicare beneficiaries with limited income and resources. The Inflation Reduction Act eliminated the partial LIS program, making full benefits available to individuals with incomes up to 150% of the federal poverty level. A New England Journal […]

Continue Reading

Invensify, Go2 Delivery Collaborate on Temperature-Controlled Courier Service

Image Credit: Adobe Stock Images/GorodenKoff.com Invensify and GO2 Delivery’s partnership significantly reduces cold chain packaging costs—by up to 50%—while ensuring regulatory compliance for temperature-sensitive medications. The collaboration promotes sustainable healthcare logistics through real-time tracking and fully carbon-neutral same-day delivery operations. Invensify, a cold chain shipper for healthcare supply chains, is collaborating with GO2 Delivery, a 100% […]

Continue Reading

White House Unveils Pharma Most-Favored-Nation Executive Order; FDA, CDC Call for Pause of Chikungunya Shot Rollout in Older Adults

White House Unveils Pharma Most-Favored-Nation Executive Order Pharmaceutical Executive reported that President Trump issued an executive order titled Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients, aiming to lower US drug prices by requiring pharmaceutical companies to match or beat prices offered in other developed countries, with potential penalties including tariffs and FDA action. FDA, […]

Continue Reading

Bluebird Bio Warns of Potential Bankruptcy as Buyout Faces Another Delay; Pharmacists Stockpile Most Common Drugs on Chance of Targeted Trump Tariffs

Bluebird bio warns of potential bankruptcy as buyout faces another delay Bluebird bio has warned of possible bankruptcy after buyers Carlyle and SK Capital extended their acquisition deadline yet again due to insufficient shareholder participation, as only about 26% of shares have been tendered—far below the required threshold to complete the deal. Pharmacists stockpile most […]

Continue Reading

Five Questions on Trump’s Plan to Lower US Drug Prices; Roche Reports Final Overall Survival Outcomes from Breast Cancer Treatment Trial

Five questions on Trump’s plan to lower US drug prices President Trump’s new plan to lower US drug prices by tying them to the lowest prices paid in other countries aims to fulfill campaign promises and pressure the pharmaceutical industry, but faces significant legal, political, and economic hurdles, with uncertain impact on actual patient costs. […]

Continue Reading

A Closer Look at NIH Grant Terminations; Simulated Pre-Launch Market Evaluation in the Modern Pharmaceutical Industry

A Closer Look at NIH Grant Terminations In an interview with Applied Clinical Trials, Harvard Medical School researcher Michael Liu discussed a recent study analyzing NIH grant terminations, revealing that 20% of the cuts affected early career training grants—critical to the biomedical research pipeline—and disproportionately impacted institutions and clinical trials serving marginalized populations. Simulated Pre-Launch […]

Continue Reading

How to Manage Rising Drug Development Costs

In a video interview with Pharma Commerce, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, describes how his company’s 15th annual Deloitte report on the return on investment (ROI) in pharmaceutical R&D reveals a continued upward trend, with a projected ROI of 5.9% for 2024. This marks a notable reversal from the consistent decline seen […]

Continue Reading

Limiting the Use of Spread Pricing

Pharmaceutical Commerce: What specific pricing practice by pharmacy benefit managers (PBMs) does the Protecting Pharmacies in Medicaid Act aim to address? Anne Cassity: The Protecting Pharmacies in Medicaid Act really aims at getting rid of spread pricing and the Medicaid managed care programs in every state in the country. Spread pricing is when pharmacy benefit […]

Continue Reading

Themes Among Rare Disease Repurposing Efforts

Image Credit: Adobe Stock Images/Suriyo.com 1. Five-step repurposing process: The study outlined a five-stage process: enabling, identifying, validating, testing, and implementing repurposed drugs. 2. RDNPs drive success: Nonprofit involvement, especially in patient recruitment, was linked to successful repurposing outcomes, including FDA approvals and off-label use. 3. New DDDR Framework: Researchers proposed a data-driven drug repurposing […]

Continue Reading

UnitedHealth Group CEO Departs

Image Credit: Adobe Stock Images/LucianoLuppa.com 1. Leadership shakeup amid crises: UnitedHealth Group CEO Andrew Witty has abruptly stepped down, citing personal reasons. His departure follows a year of major turmoil for the company, including a DOJ investigation, a massive cyberattack affecting 190 million people, and the murder of a senior executive. Former CEO and current […]

Continue Reading

Serialization System SOPs

In a video interview with Pharma Commerce, Michael Rowe, Two Labs’ senior director of DSCSA/serialization compliance services, describes how the HDA Distribution Management Conference (DMC) covers a broad spectrum of topics within the pharmaceutical supply chain, with a special focus on current regulatory and operational challenges. One of the major topics at this year’s conference […]

Continue Reading

White House Introduces Most Favored Nation EO

Image Credit: Adobe Stock Images/MAlfanSetyawan.com It’s no secret that for years, critics have commented about the prices for medication in the UnitedStates being exorbitantly high. In response to this issue, President Donald Trump yesterday unveiled a new executive order (EO)—Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients”1—meant to provide an equal playing field by having […]

Continue Reading

Piramal Pharma to Invest $90 Million in US Site Expansions

Rendering of the new Lexington sterile fill-finish facility. Image Credit: Piramal Pharma Ltd. Piramal Pharma Limited, a global pharmaceuticals and wellness company, will be investing $90 million toward growing two of the company’s plants located in the United States: Lexington, KY, and Riverview, MI.1 The expansion projects are coming into fruition following demand from US […]

Continue Reading

Teva Pharmaceutical’s Branded Drugs Boost First Quarter Profit, Theriva Biologics Announces Positive VIRAGE Phase IIb Results

Teva Pharmaceutical’s branded drugs boost first quarter profit Teva Pharmaceutical’s first-quarter profit beat expectations thanks to surging sales of key branded drugs for migraines, Huntington’s disease, and schizophrenia, as the company continues shifting toward innovative therapies while maintaining its generics focus. Theriva Biologics Announces Positive VIRAGE Phase 2b Results Theriva Biologics reported positive Phase IIb […]

Continue Reading

Teva Plots Thousands of Job Cuts as Restructuring Drive Enters ‘Acceleration’ Phase, Takeda to Invest $30B Into US Operations

Teva plots thousands of job cuts as restructuring drive enters ‘acceleration’ phase Teva is set to cut around 2,400 jobs, about 8% of its workforce, as part of its “Acceleration Phase” in the ongoing restructuring plan aimed at saving $700 million by 2027, streamlining operations, and strengthening its position in generics and innovative medicines. Takeda […]

Continue Reading

Hybrid Hub Models for the Patient Journey

In this video, Josh Marsh, Vice President and General Manager of Cardinal Health Sonexus™ Access and Patient Support, discusses the balance between technology and human interaction to support patients and programs. Patient support program strategies must be tailored to the unique needs of each patient journey, while aligning with the core competencies of the pharmaceutical […]

Continue Reading

Is the Industry Ready for the DSCSA?

In a video interview with Pharma Commerce, Michael Rowe, Two Labs’ senior director of DSCSA/serialization compliance services, describes how the HDA Distribution Management Conference (DMC) covers a broad spectrum of topics within the pharmaceutical supply chain, with a special focus on current regulatory and operational challenges. One of the major topics at this year’s conference […]

Continue Reading

Measuring What Matters

The latest wave of artificial intelligence (AI), digital health, and direct-to-patient (DTP) models have the potential to drive significant innovation, transform patient experiences, and redefine business and operating models across life science companies. Estimates show that AI alone could drive value equivalent to 11% of current revenue for a typical pharma company, while DTP models […]

Continue Reading

J&J Survey Finds Pace of Oncology Innovation is Overwhelming Physicians, Biotech is Guessing How Vinay Prasad Might Change the FDA

J&J survey finds pace of oncology innovation is overwhelming physicians A recent J&J survey reveals that oncologists are overwhelmed by the rapid pace of oncology innovation, highlighting the need for additional support and continuing medical education to help them keep up with new treatments and guidelines. Biotech is guessing how Vinay Prasad might change the […]

Continue Reading

Antares Vision Group, Siempharma Strike Up Pharma Labeling Equipment Collaboration

The ETF-300. Image Credit: Antares Vision Group Antares Vision Group, a provider of track-and-trace systems for several fields including the life sciences, is growing its solutions portfolio to now include precision labeling equipment. The company is collaborating with Siempharma, a manufacturer of packaging machines, by welcoming the ETF-300.1 This machine is capable of working with […]

Continue Reading

GLP-1 Drugs Reshape Reimbursement and Coverage Models

In an interview with Pharmaceutical Commerce, a session leader from “U.S. Pharmaceutical Transitions: What’s Next?” shared key insights on the current and future state of the market. The conversation highlighted the rapid growth of specialty pharmaceuticals—now comprising over half of the total market—and examined critical industry developments ranging from biosimilar uptake and GLP-1 drug disruption to […]

Continue Reading

SK Pharmateco Debuts New cGMP Plasmid Suite

Image Credit: Adobe Stock Images/N0m3rcy.com SK pharmteco, a contract development and manufacturing organization (CDMO), has opened a new, 300,000 square-foot current good manufacturing practice (CGMP) plasmid suite at its plant in King of Prussia, PA.1 The project demonstrates the company’s interest in a scalable supply of high-quality plasmids, which are critical in the development cell […]

Continue Reading

Tracking Long-Term Outcomes Key to Advanced Therapy Value

In an interview with Pharmaceutical Commerce, Fran Gregory, VP, emerging therapies, Cardinal Health, shared key insights into the evolving landscape of cell and gene therapies. Speaking about the current state of the market, the anticipated growth of the pipeline, and the critical steps needed to ensure long-term sustainability, Gregory highlighted both the transformative potential of these […]

Continue Reading

Digital Health and Biosimilars Shape the Future of Pharmacy

At this year’s Asembia Summit, Pharmaceutical Commerce sat down with Blake Powers, CEO of Medigi, to discuss the company’s role in bridging innovation and patient access in the life sciences space. Powers shared his insights on the evolving landscape of commercialization, the growing importance of digital health and automation, and how in-person connection at events such as […]

Continue Reading

Why AI Could Be the Key to Solving Access Challenges in Healthcare

In an interview with Pharmaceutical Commerce, Chip Parkinson, the new CEO of Gift Health, shared his perspective on stepping into the role and the evolving challenges and opportunities across the healthcare landscape. Drawing on a diverse background that spans manufacturers, payers, and employer consulting, Parkinson discussed how his new position places him in closer contact with […]

Continue Reading

Designing Smarter Interventions with Community Insights

As the healthcare industry sharpens its focus on patient-centered care, addressing social determinants of health, health equity, and literacy has become more critical than ever—particularly for individuals with chronic and rare conditions. During the “Speaking Health and Human: Bridging the Gap to Quality Patient Care” session, Tiara Green will join industry leaders to explore how barriers to […]

Continue Reading

ABM’s Digital Solution for Good Manufacturing Practices

March 14th 2025 Article A regional hospital serving suburban Indianapolis, Hancock Regional Hospital faced a familiar challenge: disparate monitoring systems that taxed their staff and too many manual processes that drove inefficiencies. CEO Steve Long greenlit a solution: a consolidated temperature, environmental, and sound monitoring program that protected precious assets, automated tedious compliance, and freed […]

Continue Reading

Understanding the Inflation Reduction Act

Image Credit: Nicholas Saraceno The afternoon of day 2 at Asembia’s AXS25 Summit offered various intriguing sessions to pick from, including one on “Navigating the IRA: What Have We Learned? What is on the Horizon?” The IRA—or Inflation Reduction Act—is a federal law passed in 2022 that, among its various purposes, aims to lower prescription […]

Continue Reading

Rethinking the Drug Distribution Process

Image Credit: Nicholas Saraceno The final day of education at Asembia’s AXS25 Summit kicked off with a multitude of early morning sessions, including one focused on “Beyond Limits: Rethinking Drug Distribution to Drive Patient-Centered Care.” Led by Mike Reff, RPh, MBA, executive director and founder of NCODA (Network for Collaborative Oncology Development & Advancement), he […]

Continue Reading

Addressing Polypharmacy Challenges in Europe with Real World Evidence

Multimorbidity and associated polypharmacy, including use of potentially inappropriate medication (PIM), are an increasing challenge for European health systems. A lack of cross-national studies using standardized methodology and comparable study populations makes it difficult to determine the prevalence of polypharmacy and PIM use in primary care across Europe. In a recent study, “The prevalence of […]

Continue Reading

The Cost of Care for Patients

Image Credit: Nicholas Saraceno The afternoon sessions here on day 3 of Asembia continued its impressive slate, with its various business seminars as proof. One of which was centered around “The Cost of Care for Patients: Navigating the Financial Assistance Landscape.” Moderated by Amy Niles, chief mission officer of the PAN Foundation and Pharm Commerce […]

Continue Reading

What Pharma Leaders Must Know About Tariffs, Supply Chains, and Policy Changes

The second day of Asembia’s AXS25 Summit featured a session that addressed a distinct set of challenges facing the pharmaceutical industry. Titled “Beyond the Headlines: What Pharma Leaders Must Know About Tariffs, Supply Chains, and Policy Changes,” the discussion highlighted how evolving global instability, policy shifts, and supply chain vulnerabilities are reshaping access and strategy […]

Continue Reading

How Specialty Pharmacies Are Evolving to Support Rare Conditions

In an interview with Pharmaceutical Commerce, Will Pih, co-founder, Two Labs, shared insights from his recent panel discussion on “Economics and Specialty Pharmacy for Rare Diseases: Challenges and Opportunities.” The conversation explored the growing complexities of delivering care in the rare disease space, particularly as specialty pharmacies and pharmaceutical manufacturers navigate high drug costs, small […]

Continue Reading

Therapy Advancements Highlight Growing Cost and Access Concerns

In an interview with Pharmaceutical Commerce, Fran Gregory, VP, emerging therapies, Cardinal Health, shared key insights into the evolving landscape of cell and gene therapies. Speaking about the current state of the market, the anticipated growth of the pipeline, and the critical steps needed to ensure long-term sustainability, Gregory highlighted both the transformative potential of […]

Continue Reading

Rare Disease Therapies Drive Shift in Drug Development Focus

In an interview with Pharmaceutical Commerce, a session leader from “U.S. Pharmaceutical Transitions: What’s Next?” shared key insights on the current and future state of the market. The conversation highlighted the rapid growth of specialty pharmaceuticals—now comprising over half of the total market—and examined critical industry developments ranging from biosimilar uptake and GLP-1 drug disruption […]

Continue Reading

Navigating the Product Commercialization Process

Image Credit: Nicholas Saraceno Here at Asembia’s AXS25 Summit in Las Vegas, attendees were treated to behind-the-scenes insight regarding “Commercialization Considerations for Orphan/Rare, Cell & Gene, and Precision Medicine.” Led by Brett Casper, a senior principal at Blue Fin Group, his agenda revolved around outlining the evolving orthodoxies for commercialization of ORD, CGT, and precision […]

Continue Reading

Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation, Trump Assessing Slashing US Drug Prices to International Levels

Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation Regeneron and Roche are investing a combined $53 billion over the next decade to expand US manufacturing and R&D infrastructure—spanning biologics, gene therapy, AI-driven research, and next-gen therapeutics—in response to rising global demand and potential US pharmaceutical tariffs, with Regeneron […]

Continue Reading

Understanding True Meaning of Risk in Clinical Trial Operations, European Pharma Companies Push for Higher Drug Prices Amid US Tariff Threats

Understanding the True Meaning of Risk in Clinical Trial Operations In a recent interview with Applied Clinical Trials, Rob Jones of Pharmalex emphasized the need for TMF leaders to adopt a truly risk-based, quality-by-design mindset. This includes embracing innovations such as AI, focusing on critical records, and adapting to rapidly evolving regulations such as ICH […]

Continue Reading

Roche in ‘Very, Very Good Position’ To Weather Trump Tariffs but M&A May Suffer, Thermo Fisher to Invest Addlitional $2 Billion In US To Boost Manufacturing

Roche in ‘Very, Very Good Position’ To Weather Trump Tariffs but M&A May Suffer Roche expects to weather the financial impact of Trump-era tariffs due to its strategic US manufacturing shifts and global investments, though M&A activity may slow as the industry assesses the tariffs’ broader implications. Thermo Fisher To Invest Addl. $2 Bln In […]

Continue Reading

The Future of Specialty Medicine

In a video interview with Pharma Commerce, Paul Levesque, CEO of Theratechnologies, explains how Theratechnologies’ operations have been impacted by recent US tariffs on Canadian goods, especially concerning the manufacturing and supply chain for its HIV therapy, EGRIFTA SV. The active ingredients used in EGRIFTA SV come from the US, travel to Canada for additional […]

Continue Reading

PCI to Purchase Full Stake in Ajinomoto Althea

Image Credit: Business Wire PCI Pharma Services, a contract development and manufacturing organization (CDMO), will be purchasing a full stake in Ajinomoto Althea, Inc., a sterile fill-finish CDMO and subsidiary of Japan-based Ajinomoto Co., Inc., for an undisclosed amount.1 The deal is anticipated to be completed by May, and gives PCI its first-ever North American […]

Continue Reading

Reducing Polypharmacy in Older Adults

Image Credit: Adobe Stock Images/Kotchakorn.com Among the older population, polypharmacy—the use of five or more medications—has skyrocketed. The issue lies in the fact that some meds lack any sort of indication, are used in way too high of a dose, or do more harm than good. These are considered “inappropriate.” As a result, there has […]

Continue Reading

Driving Business Success Through Sustainability

PC: You just wrapped up a panel discussion on “Uniting on Sustainability: How can we drive collaboration and ground-breaking initiatives to ensure ESG is a top business priority?” With sustainability being such a priority nowadays, what were some the highlights of the presentation? Ganguly: The panel was actually really refreshing because we moved away from […]

Continue Reading

Preparing for DSCSA Deadlines

In a video interview with Pharma Commerce, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, outlines his vision for the future of the organization and the key priorities he hopes to drive during his tenure. He expresses a strong sense of privilege and responsibility in succeeding Kirk Kaminsky and […]

Continue Reading

Why Patient Empowerment is Key

In a video interview with Pharma Commerce, Rachel Thorpe, executive director at the Otsuka Patient Assistance Foundation, discusses two key sessions: “Establishing and Transitioning to a Foundation” and “Empowering Patients to Take Control of Their Healthcare.” The first session focuses on the important aspects of transitioning to a foundation, emphasizing the risks associated with regulations […]

Continue Reading

Pharma Companies Expected to Absorb Any Tariff Hit in Short Term, New Chronic Antigen Exposure Data, & more

Pharma companies expected to absorb any tariff hit in short term While US tariffs on pharmaceuticals may eventually raise drug prices, especially for generics, experts say brand-name costs will likely be absorbed by manufacturers in the short term—impacting profits, research, and staffing—while the broader goal may be to pressure companies into narrowing the price gap […]

Continue Reading

FDA Grants Interchangeability Designation to Celltrion’s Humira Biosimilar Yuflyma

Image Credit: Adobe Stock Images/Monchisa The FDA has granted interchangeability designation to Celltrion’s Yuflyma (adalimumab-aaty), a high-concentration (100 mg/mL), citrate-free biosimilar of Humira (adalimumab), across multiple inflammatory indications. The designation allows pharmacists, subject to state laws, to substitute Yuflyma for Humira without prescriber intervention, which could potentially improve access and lower costs for patients.1 “With […]

Continue Reading

Bringing Biotech Innovation Across Borders, Role of Collaboration in Advancing Rare Disease Research

Bringing Biotech Innovation Across Borders A feature published by Pharmaceutical Executive authored by Ed Ahn, CEO of MEDIPOST, Inc, outlines four tips for midsized companies when entering new global markets. The Role of Collaboration in Advancing Rare Disease Research In this video interview published by Applied Clinical Trials, Derek Ansel, vice president, therapeutic strategy lead, […]

Continue Reading

The Quest to Deliver Reliability

In a video interview with Pharma Commerce, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, outlines his vision for the future of the organization and the key priorities he hopes to drive during his tenure. He expresses a strong sense of privilege and responsibility in succeeding Kirk Kaminsky and […]

Continue Reading

Lessons from Life Sciences and Beyond

For a child with autism spectrum disorder (ASD), effective care coordination across the required medical, physical rehabilitation, counseling, occupational, and speech providers is challenging, especially when the aim is to provide individualized care—at scale across many patients. Genial Care, a healthcare company focusing on personalized interventions for children with ASD, provides a successful example of […]

Continue Reading

The Real Work Behind the Annual Program

PC: How do you manage to keep the program itinerary organized year after year? Robinson: While we have a broader global LogiPharma portfolio, my team now focuses solely on this event. These days, it’s a year-round project—365 days. Once this year’s event wraps, I’ll be thanking our speakers and delegates and immediately starting research conversations […]

Continue Reading

Leading with Purpose

In a video interview with Pharma Commerce, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, outlines his vision for the future of the organization and the key priorities he hopes to drive during his tenure. He expresses a strong sense of privilege and responsibility in succeeding Kirk Kaminsky and […]

Continue Reading

Meribel Pharma Solutions Joins the CDMO Marketplace

Image Credit: Adobe Stock Images/Metamorworks.com There is a new contract development and manufacturing organization (CDMO) in the marketplace. With the ultimate goal of boosting patient health through its manufacturing services, Meribel Pharma Solutions has officially launched, bringing with it a European network of clients.1 The name comes from the Meribel mountain range in the Alps. This particular […]

Continue Reading

April 2025 Interactive Digital Edition

Pharmaceutical Commerce: April 2025 Interactive Digital Edition The Cold Chain’s Evolution Tariffs Galore: Where Do We Stand? Conference Connect: Progressing Patient Assistance The Hot Market for Cold Chain Services Reducing Risk in the Pharmaceutical Cold Chain An AI-Pharma Transport Collaboration The Role of CDMOs in the Pharma Cold Chain Machine From Prescription to Patient: Four […]

Continue Reading

The Role of CDMOs in the Pharma Cold Chain Machine

The pharmaceutical cold chain sector plays a crucial role in ensuring the safe and effective delivery of temperature-sensitive medications, including advanced therapy medicinal products (ATMPs). For the last decade, it’s been crucial for contract development and manufacturing organizations (CDMOs) to adopt the latest technological advances to enhance the efficiency and reliability of the cold chain, […]

Continue Reading

An AI-Pharma Transport Collaboration

Logistics play a very important role in the pharmaceutical industry, as the activities involved are highly sensitive to time and quality control. It involves delivering drugs to the right place, at the right time, in a safe and secure manner, and at a competitive operational cost. Given this crucial nature of activities, drug shipping faces […]

Continue Reading

Long-Term Sustainability for Diverse Trial Initiatives, Payers Consider Policy Options for GLP-1 Access & more

Long-Term Sustainability for Diverse Trial Initiatives LaShell Robinson, head of global feasibility and trial equity at Takeda, discusses how Takeda will ensure that diversity and inclusion remain a priority in its clinical trials moving forward. Payers Consider Policy Options for Access to GLP-1 Obesity Medications A new paper by the Institute for Clinical and Economic […]

Continue Reading

Hubs East 2025: Building a Thriving Culture

In a video interview with Pharma Commerce, Kimberly Westrich, MD, chief strategy offer at the National Pharmaceutical Council, describes how in response to rising healthcare costs, employers have turned to high-deductible health plans and higher out-of-pocket (OOP) expenses, causing patients to pay more for healthcare. To help alleviate this financial burden, manufacturers offer copay assistance […]

Continue Reading

Four Ways to Increase Speed to Therapy

Let’s start with an alarming pair of statistics. First, 40% of specialty product prescriptions actually get filled, and second, when a patient’s copay or out-of-pocket cost exceeds $250, the abandonment rate is nearly 70%. Pharmaceutical manufacturers are focused on making massive investments in product launches, field force training, marketing, and healthcare provider (HCP) education, but […]

Continue Reading

Healthcare Scorecard from Patients with Chronic Illness

Healthcare costs, insurance barriers, and medical debt are preventing patients with chronic illnesses in the US from accessing essential treatments and medications. That’s according to the PAN Foundation’s Center for Patient Research State of Patient Access Report initiative. The latest survey1, released in March, found patients living with chronic health conditions rated the overall state […]

Continue Reading

Reevaluating One’s CGT Value Chain

Image Credit: Nicholas Saraceno LogiPharma Europe continued its star-studded lineup featuring Big Pharma, with a morning keynote case study on “Rethinking Your C&GT Value Chain: How to Ensure Readiness for Evolving Specialized Therapy Requirements.” Led by Graham White, BMS’ executive director of global delivery for Europe, the Middle East, and Africa (EMEA), he sought out […]

Continue Reading

US Drug Price Negotiations and Transparency

When I was penning my latest column for Pharma Commerce, I felt that various recent developments were worth noting, considering the impact they could have on the US prescription drug market. They include the drug industry’s push to make Inflation Reduction Act (IRA) changes to the “pill penalty” and negotiation eligibility timing for orphan drugs, […]

Continue Reading

GenAI’s Real Impact on Life Sciences Manufacturing

The COVID-19 pandemic highlighted our supply chains’ weaknesses like never before. A sudden surge in demand and limited production capabilities led to critical shortages of medical supplies, pharmaceuticals, and even basic consumer goods. For life sciences, this disruption wasn’t just a matter of lost revenue—it was a matter of life and death. In this high-stakes […]

Continue Reading

Maintaining R&D Investments in the IRA Era

Developing effective lifesaving drugs requires significant research and development (R&D) investments. New medications cost an average of $2.3 billion to develop,1 largely funded by existing drug sales. At the same time, pharmaceutical companies are under increasing pressure from the government to reduce prescription prices, which presents a significant hurdle to maintaining the R&D pipeline. Industry […]

Continue Reading

How Various Programs Affect Patient Care and Health Equity

In a video interview with Pharma Commerce, Kimberly Westrich, MD, chief strategy offer at the National Pharmaceutical Council, describes how in response to rising healthcare costs, employers have turned to high-deductible health plans and higher out-of-pocket (OOP) expenses, causing patients to pay more for healthcare. To help alleviate this financial burden, manufacturers offer copay assistance […]

Continue Reading

Boehringer Ingelheim Opens $31.5 Million Oncology Antibody-Drug Conjugate Facility in Switzerland

Image Credit: Adobe Stock Images/MichaelVi Boehringer Ingelheim announced the official opening of a new antibody-drug conjugate (ADC) research and development facility in Basel, Switzerland, through its wholly owned subsidiary, NBE Therapeutics. According to the company, the $31.5 million facility will serve as a global hub for advancing the development of ADCs and is designed to […]

Continue Reading

Balancing Cost-Efficiency with Domestic Manufacturing Need, Making M3P Work for Your Pharmacy & more

Balancing Cost-Efficiency with the Need for Domestic Manufacturing Marcel Botha, CEO of 10XBeta, discusses finding a balance between the need for cost-efficiency and the need to build domestic manufacturing capacity for essential medical devices. Making M3P Work for Your Pharmacy: A Guide to Streamlining Enrollment and Supporting Patients M3P will be a financial lifeline for […]

Continue Reading

Analyzing the Theranos Appeals, Current CAR-T Therapy Trends in Managed Care & more

Analyzing the Theranos Appeals Matthew Yelovich, partner at Cleary Gottlieb, discusses the appeals of Elizabeth Holmes and Ramesh “Sunny” Balwani and the Ninth Circuit’s recent affirmation of their convictions. Current CAR-T Therapy Trends in Managed Care | AMCP Annual 2025 Balancing the cost, access to and risk management of CAR-T cell therapies is critical, according […]

Continue Reading

Establishing and Transitioning to a Foundation

In a video interview with Pharma Commerce, Rachel Thorpe, executive director at the Otsuka Patient Assistance Foundation, discusses two key sessions: “Establishing and Transitioning to a Foundation” and “Empowering Patients to Take Control of Their Healthcare.” The first session focuses on the important aspects of transitioning to a foundation, emphasizing the risks associated with regulations […]

Continue Reading

Reasons Behind the Rising Popularity of DTC Online Prescription Services

In a video interview with Pharma Commerce, Colin Banas, MD, DrFirst’s chief medical officer, describes have many Americans face significant challenges in accessing GLP-1 drugs due to their high cost. Despite the growing popularity and usage of these medications, which were originally developed for diabetes treatment, the price remains largely unchanged. Even with insurance coverage, […]

Continue Reading

Siemens Inks $5.1 Billion Deal for Dotmatics

Image Credit: Adobe Stock Images/Tun.com Siemens AG, a technology conglomerate, has acquired Dotmatics, an R&D scientific software company, from private equity firm Insight Partners for $5.1 billion.1 “By acquiring Dotmatics, we’re strategically strengthening our position in life sciences and creating a world-leading AI-powered PLM software portfolio as part of Siemens Xcelerator. Artificial intelligence has emerged […]

Continue Reading

The Growing Role of DTC Healthcare

In a video interview with Pharma Commerce, Colin Banas, MD, DrFirst’s chief medical officer, describes have many Americans face significant challenges in accessing GLP-1 drugs due to their high cost. Despite the growing popularity and usage of these medications, which were originally developed for diabetes treatment, the price remains largely unchanged. Even with insurance coverage, […]

Continue Reading

Trump Issues New Reciprocal Tariffs

Image Credit: Adobe Stock Images/Bashirlrshad.com Yesterday afternoon, as reported by AP,1 US President Donald Trump announced that he will be enacting reciprocal tariffs on countries that are running trade surpluses with the United States—which is when the value of its exports exceeds the value of its imports. In other words, these are the nations in […]

Continue Reading

Understanding Copay Accumulators, Maximizers, and Alternative Funding Programs

In a video interview with Pharma Commerce, Kimberly Westrich, MD, chief strategy offer at the National Pharmaceutical Council, describes how in response to rising healthcare costs, employers have turned to high-deductible health plans and higher out-of-pocket (OOP) expenses, causing patients to pay more for healthcare. To help alleviate this financial burden, manufacturers offer copay assistance […]

Continue Reading

Hims & Hers Begins Selling Zepbound

Image Credit: Adobe Stock Images/Douglas.com A Reuters report1 noted that Hims & Hers began selling various Eli Lilly drugs on their platform—both branded forms of tirzepatide—including Zepbound, a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for weight loss, and Mounjaro, which is not approved for weight loss but for the treatment of type […]

Continue Reading

DHL Purchases Cryoport’s Specialty Courier

Oscar de Bok, CEO of DHL Supply Chain, and Jerrell Shelton, CEO of Cryoport. Image Credit: DHL Supply Chain DHL has purchased CRYOPDP, Cryoport’s specialty courier powered by clinical trials, biopharma, and cell and gene therapies.1 In that same breath, the parties also noted that they’ve reached a strategic partnership that’s intended to augment both […]

Continue Reading

Balancing Technology, Personalization, and Human Connection in Patient Support

PC: What are some of the biggest challenges in ensuring continued medication adherence for specialty patients? Butler: While technology and high-touch support are important, personalization is equally critical. Emotions fluctuate daily, and medication regimens, as well as chronic conditions, evolve over time. Whenever we implement a solution, we must continuously check in to ensure patients […]

Continue Reading

How Engagement Strategies Are Evolving in Specialty Pharmacy

PC: How is the role of patient engagement evolving in specialty pharmacy? Butler: It’s becoming increasingly critical to evolve patient support in specialty pharmacy, as patients now expect more personalized care. With the rapid advancement of technology, they also anticipate greater connectivity. While access to information is beneficial, it can also be overwhelming. From struggling […]

Continue Reading

Singota Solutions Opens New Plant in Balerna, Switzerland

Image Credit: Singota Solutions Following the launch of last year’s site in Rovello Porro, Italy,1 Singota Solutions, a contract development and manufacturing organization (CDMO), has opened a new 100,000 square-foot plant in Balerna, Switzerland.2 Balerna is located near the Swiss-Italian border, providing the CDMO’s customers with a convenient location for reaching various European rail and […]

Continue Reading

The Role of Emotional Support in Improving Patient Adherence

PC: What are some common barriers patients face when starting specialty medications, and how can peer-to-patient outreach help? Butler: Our program is a peer-to-patient platform, which I believe is critical. It addresses emotional barriers such as fear, misinformation, mistrust, anxiety, feeling overwhelmed, not knowing who to turn to, uncertainty about the process, and concerns about […]

Continue Reading

LillyDirect Platform to Help Provide Alzeheimer’s Support

Image Credit: Adobe Stock Images/Orawan.com Eli Lilly and Company is growing its LillyDirect digital healthcare platform to offer independent in-person and telehealth support for people in the United States that are living with Alzheimer’s disease, many of whom may have not been officially diagnosed.1,2 Clinicians and those living with Alzheimer’s disease have conveyed the value of boosting […]

Continue Reading

Hubs East 2025: Navigating Specialty Medication Onboarding

PC: How does Pleio’s GoodStart program assist specialty pharmacies in improving patient engagement and adherence? Butler: Onboarding onto specialty medications is a complex and often overwhelming process for patients. That’s the core challenge Pleio addresses with our GoodStart program. We focus on delivering patient-centric support to specialty pharmacies through a comprehensive, wraparound solution. Our approach […]

Continue Reading

Balancing Technological & Human Support in Medication Access, How PBMs’ Vertical Integration Impacts Health Care & more

Balancing Technological & Human Support in Medication Access Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, addresses patient and prescriber expectations for digital health tools. Educate Patients About How PBMs’ Vertical Integration Impacts Their Health Care Although PBMs claim integration reduces costs and improves efficiency, the reality is more complicated—and often leaves patients […]

Continue Reading

Futureproofing Pharma Supply Chains

In a video interview with Pharma Commerce, Brad Stewart, BDO’s national life sciences co-leader, describes the challenges that tariffs may pose to reshoring manufacturing services in the life sciences industry. He highlights the complexity of supply chains in this sector, which are large, long, highly-regulated, and slow to change. Given that future administrations may alter […]

Continue Reading

Examining Healthcare Spending Across US Counties

Image Credit: Adobe Stock Images/Gaming.com Although the United States spends an exorbitant amount on healthcare, amounts across the individual states vary. In fact, studies have so that there are some counties that spend more than five times as much per person as other counties.1,2 Such variety in public, commercial, and out-of-pocket (OOP) spending can help […]

Continue Reading

The Unfinished Work of Healthcare Reform

Charitable donations have long been a vital lifeline for patients struggling to afford life-saving medications, particularly those with chronic and rare diseases. Over the past few decades, various assistance programs—including nonprofit safety nets, third-party organizations, and manufacturer-sponsored free drug initiatives—have emerged to bridge the gap between medical advancements and patient affordability. However, despite these efforts, […]

Continue Reading

Hubs East 2025: The Patient Access Landscape

Image Credit: Nicholas Saraceno The final day of Informa’s Access USA conference arrived quickly, and I decided to attend a session along the Hubs East track focused on “The Changing Landscape of Patient Access—Accumulators, Maximizers & Alternative Funding.”1 Featuring Meredith McDonald, director of patient access, Exelixis; Kimberly Westrich, National Pharmaceutical Council; and Vicki Karlan, US […]

Continue Reading

Spreading Awareness of Medicare Part D Reforms

Image Credit: Nicholas Saraceno Informa’s Access USA conference from Philadelphia continued with its first panel discussion of the conference. Amy Niles, chief mission officer of the PAN Foundation—a national charitable foundation and healthcare advocacy group—was joined by Bill Allen, a patient and family advisory council member with PAN Foundation; Susan Neff, aging services supervisor and […]

Continue Reading

How Charitable Programs Are Evolving to Improve Patient Access to Life-Saving Medications

Charitable donations have long been a vital lifeline for patients struggling to afford life-saving medications, particularly those with chronic and rare diseases. Over the past few decades, various assistance programs—including nonprofit safety nets, third-party organizations, and manufacturer-sponsored free drug initiatives—have emerged to bridge the gap between medical advancements and patient affordability. However, despite these efforts, […]

Continue Reading

New Ways of Targeting Cancer, How Employers Can Support Employee Well-Being and Mental Health & more

New Ways of Targeting Cancer Company executives provide updates on cancer treatment pelareorep and other elements of the company’s pipeline. How Employers Can Support Employee Well-Being and Mental Health Trust remains a sensitive subject amongst employees as the shortage of mental health resources makes it even harder for them to build that trust with employers. […]

Continue Reading

The Biggest Bottlenecks for Patients, Age and Comorbidities Drive RSV Hospitalization Rates & more

The 2025 Medication Access Report: Biggest Bottlenecks for Patients Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, highlights gaps in data sharing and cross-functional collaboration as major bottlenecks that are causing delays, rework, and increased patient burden. Age and Comorbidities Drive RSV Hospitalization Rates in Older Adults Prioritizing preventive measures for high-risk individuals […]

Continue Reading

The Ongoing Challenge for Nonprofit Patient Assistance Programs

Charitable donations have long been a vital lifeline for patients struggling to afford life-saving medications, particularly those with chronic and rare diseases. Over the past few decades, various assistance programs—including nonprofit safety nets, third-party organizations, and manufacturer-sponsored free drug initiatives—have emerged to bridge the gap between medical advancements and patient affordability. However, despite these efforts, […]

Continue Reading

PAP 2025: Boosting Patient Empowerment

Image Credit: Nicholas Saraeno Day 2 of Informa’s Access USA track-based coverage carried on, with an afternoon session on the PAP track being run by Rachel Thorpe, executive director at the Otsuka Patient Assistance Foundation, an independent entity from the manufacturer Otsuka. Focusing on “Empowering Patients to Take Control of Their Healthcare,” the session aimed […]

Continue Reading

PAP 2025: Understanding the Uninsured Landscape

Image Credit: Nicholas Saraceno Day 2 of Informa’s Access USA conference represented the start of its track-based sessions. In terms of the patient assistance & access program (PAP) focus of the conference, Aaron Winn, associate professor at the University of Illinois Chicago, led off the morning with a presentation centered around “Understanding the Uninsured Landscape.”1 […]

Continue Reading

The Impact of Out-of-Pocket Costs on Patients with Rare Diseases

Charitable donations have long been a vital lifeline for patients struggling to afford life-saving medications, particularly those with chronic and rare diseases. Over the past few decades, various assistance programs—including nonprofit safety nets, third-party organizations, and manufacturer-sponsored free drug initiatives—have emerged to bridge the gap between medical advancements and patient affordability. However, despite these efforts, […]

Continue Reading

Access USA 2025: Uncovering Patient Access Complexities

Image Credit: Nicholas Saraceno Informa’s Access USA conference leveraged its KOL base with a roundtable on “Unravelling the Complexities of Patient Access and Affordability.”1 Featuring Ian Ocilka, ConnectiveRx’s chief strategy officer as moderator, he was accompanied by Nancy Bell, vice president and head of market access at Celcuity; Shannon Ashmon, lead, patient services–oncology, US market access at […]

Continue Reading

How Charitable Programs Are Evolving to Improve Patient Access to Life-Saving Medications

Charitable donations have long been a vital lifeline for patients struggling to afford life-saving medications, particularly those with chronic and rare diseases. Over the past few decades, various assistance programs—including nonprofit safety nets, third-party organizations, and manufacturer-sponsored free drug initiatives—have emerged to bridge the gap between medical advancements and patient affordability. However, despite these efforts, […]

Continue Reading

This Year’s State of the Industry

Image Credit: Nicholas Saraceno Day 1 of Informa’s Access USA Conference from Philadelphia—featuring Patient Assistance & Access Programs (PAP) and Hub and Specialty Models East—was kicked off by Tommy Bramley, Cencora’s SVP of global consulting services. Titled “State of the Industry—The Evolving Landscape of Healthcare Coverage and Access in 2025,”1 the goal of the Access USA […]

Continue Reading

How Pharma Leaders Can Secure Supply Chains

In a video interview with Pharma Commerce, Brad Stewart, BDO’s national life sciences co-leader, describes the challenges that tariffs may pose to reshoring manufacturing services in the life sciences industry. He highlights the complexity of supply chains in this sector, which are large, long, highly-regulated, and slow to change. Given that future administrations may alter […]

Continue Reading

Hancock Health Case Study: Pharmacy Temperature Monitoring

March 14th 2025 Article Transitioning from manual temperature logs and reactive power outage management to a comprehensive cloud-based monitoring solution, Discount Drug Mart has revolutionized its approach to pharmacy operations and compliance. Adopting Sonicu’s advanced system, this Ohio-based retail pharmacy chain now benefits from seamless temperature monitoring and real-time power outage alerts across its 77 […]

Continue Reading

How Sonicu supports remote clinics and pharmacists with a 24/7 cloud-based remote monitoring solution

March 14th 2025 Article A regional hospital serving suburban Indianapolis, Hancock Regional Hospital faced a familiar challenge: disparate monitoring systems that taxed their staff and too many manual processes that drove inefficiencies. CEO Steve Long greenlit a solution: a consolidated temperature, environmental, and sound monitoring program that protected precious assets, automated tedious compliance, and freed […]

Continue Reading

Pre-Launch Prep for Emerging Biopharmas, Using the Power of Three to Simplify the Business of Healthcare & more

Pre-Launch Prep for Emerging Biopharmas: Data First, Then the Rest Making early commercial data and analytics decisions for launch cen future-proof their data management. The Power of Three To Help Simplify the Business of Healthcare The healthcare industry faces unprecedented complexity impacting business stakeholder operations, from managing extensive documentation requirements to protecting sensitive patient data […]

Continue Reading

Cold Chain Technologies Inks Deal for Global Cold Chain Solutions

Image Credit: Adobe Stock Images/WatermillStudio.com Cold Chain Technologies (CCT), a US-based provider of thermal packaging and digital monitoring solutions for the transportation of temperature-sensitive life sciences products, has acquired Global Cold Chain Solutions (GCCS), a provider of passive cold chain solutions based in Australia and India, for an undisclosed amount.1 GCCS is a creator of thermal assurance solutions […]

Continue Reading

Syngene Purchases First US Manufacturing Facility for $36.5M

In a transaction officially set to close later this month, Syngene International Limited, a contract research, development, and manufacturing organization (CRDMO), acquired its first biologics site in the United States for $36.5 million.1 Equipped with multiple monoclonal antibody (mAbs) manufacturing lines, the state-of-the-art biologics facility in Baltimore was officially purchased by Syngene USA Inc.—a wholly owned subsidiary of […]

Continue Reading

PharmaCord, Mercalis Merge in an Effort to Support the Patient Journey

Image Credit: Adobe Stock Images/Mrzproducer.com PharmaCord LLC, a provider of patient services for the biopharmaceutical industry, and Mercalis, a life sciences commercialization partner, are merging to create a “total solutions provider” for the biopharma sector that is expected to offer solutions ranging from patient services to market access, in an effort to cover the entire […]

Continue Reading

Unlocking the Potential of Cell and Gene Therapies

In a video interview with Pharma Commerce, Jason C. Foster, CEO of Ori Biotech, describes how the current state of cell and gene therapies (CGTs) shows promising potential, particularly in curing cancer and rare diseases. These therapies are safe and effective, with evidence demonstrating their curative capability. However, their widespread adoption is hindered by challenges […]

Continue Reading

The Case for Reshoring Manufacturing to the United States

In a video interview with Pharma Commerce, Brad Stewart, BDO’s national life sciences co-leader, describes the challenges that tariffs may pose to reshoring manufacturing services in the life sciences industry. He highlights the complexity of supply chains in this sector, which are large, long, highly-regulated, and slow to change. Given that future administrations may alter […]

Continue Reading

Strategic Trends in Pharmaceutical Manufacturing for Industry Leaders

The pharmaceutical manufacturing sector is experiencing a profound transformation driven by technological advancements, regulatory shifts, and market dynamics. Industry leaders are facing both unprecedented challenges and opportunities, making it essential to adopt new strategies to stay competitive. Innovations in manufacturing technologies, coupled with growing demands for personalized medicine and sustainability, are reshaping the landscape. Moreover, […]

Continue Reading

Tariff Impact on Medication Availability/Accessibility for Telehealth Patients, Addressing the Gap in Type 1 Diabetes Care & more

Potential Tariff Impact on Availability & Accessibility of Medications for Telehealth Patients In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry, highlighting that tariffs will initially affect pharmaceutical companies, particularly those dealing with branded medications and generics. He notes that tariffs could […]

Continue Reading

Regulatory Agencies Role in Battle Against Misinformation, Developing Winning Supplemental Benefits Packages & more

The Role Regulatory Agencies Should Play in the Battle Against Misinformation In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, explores what kind of role regulatory agencies should play in the battle against misinformation. Developing Winning Supplemental Benefits Packages Facing a variety of financial pressures, health plans need to take a […]

Continue Reading

Trump Delays Certain Tariffs on Canada and Mexico

Image Credit: Adobe Stock Images/MariusFaust.com A couple days following a tax that had gone into effect on various goods coming in from Canada and Mexico, President Trump has decided to postpone several of his previously announced1 25% tariffs on these trading partners after a concern for economic consequences—reported AP2—as he signed executive orders making it […]

Continue Reading

Streamlining Prescription Processes

In a video interview with Pharma Commerce, Tom Dorsett, CEO, RazorMetrics, describes how polypharmacy refers to the use of five or more medications by an individual, and it is becoming an increasingly prominent issue in the United States. Polypharmacy has been recognized for years but is growing more significant, especially within Medicaid, Medicare, and large […]

Continue Reading

Astellas, YASKAWA Partner to Form New Cell Therapy Manufacturing Joint Venture

Image Credit: Adobe Stock Images/PinkEyes.com Astellas Pharma and YASKAWA Electric Corporation have signed a definitive agreement that officially commences a joint venture that revolves around the design of a cell therapy product manufacturing platform using Maholo, a dual-armed, humanoid robot created by the Robotic Biology Institute, a YASKAWA subsidiary.1 The partnership is expected to provide […]

Continue Reading

Overcoming Health Data Blockages in Polypharmacy

In a video interview with Pharma Commerce, Tom Dorsett, CEO, RazorMetrics, describes how polypharmacy refers to the use of five or more medications by an individual, and it is becoming an increasingly prominent issue in the United States. Polypharmacy has been recognized for years but is growing more significant, especially within Medicaid, Medicare, and large […]

Continue Reading

Understanding the Legal Implications of Tariffs on the Pharma Supply Chain and Prescription Drug Pricing

PC: What are the legal implications of the latest tariffs—including the “reciprocal” variety—and what challenges do they present to the pharma supply chain? Lanton: Reciprocal tariffs could create significant disruptions in the supply chain and many commercial contracts. I don’t want to get overly technical, but many contracts include clauses that activate certain procedures or […]

Continue Reading

Tariffs on Canada and Mexico Now Official

It’s official—Trump’s tariffs on Canada and Mexico have now taken effect. In what the US president says is being tied to the threat posed by illegal aliens and drugs, including fentanyl, a 25% tariff has been implemented on imports from Canada and Mexico, with certain assets being taxed differently, such as Canadian energy resources, including […]

Continue Reading

Keys to Advancing HCP Engagement

The landscape of healthcare provider (HCP) engagement has undergone a fundamental transformation. While traditional face-to-face interactions remain valuable, today’s HCPs interact across multiple channels throughout their day—from websites to social media platforms, professional forums, and digital portals. This evolution demands a sophisticated approach to engagement that meets HCPs where they are with content that adds […]

Continue Reading

Delivering Personalized Experiences at Scale, Combat Counterfeit Medications & more

Delivering Personalized Experiences at Scale: A Fresh Look at Customer Centricity Customer centricity. An overused buzzword in the life sciences industry. Yet an important goal. In an era of eroding rep access, fragmented channels and growing complexity in treatment decisions, building a customer-centric commercial operation is more difficult than ever. Combat Counterfeit Medications When educating patients, […]

Continue Reading

Will Tariffs Affect Branded Drug Prices?

In a video interview with Pharma Commerce, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California (USC, describes how the 10% tax on Chinese goods and a potential 25% tariff on pharmaceuticals could have notable effects on the price, quality, […]

Continue Reading

Lilly to Build Four New US Manufacturing Facilities

Image Credit: Adobe Stock Images/StockMarketVisuals.com In an effort to increase its domestic medicine production across various therapeutic areas, Eli Lilly and Company will be constructing four new pharmaceutical manufacturing sites in the United States, representing financial commitments in the expansion space exceeding $50 billion since the start of 2020.1 The news comes off the heels of President […]

Continue Reading

Impact of Tariffs on the Generic Drug Market

In a video interview with Pharma Commerce, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California (USC, describes how the 10% tax on Chinese goods and a potential 25% tariff on pharmaceuticals could have notable effects on the price, quality, […]

Continue Reading

Trump Signs Healthcare Price Transparency Executive Order

Image Credit: Adobe Stock Images/AvectStock.com President Trump recently signed an executive order providing greater healthcare price transparency for patients.1 The order, says the Trump Administration, is expected to help lower healthcare prices, which will ultimately benefit patients and employers when it comes to seeking out deals on healthcare. Per Reuters,2 the Departments of the Treasury, […]

Continue Reading

Lilly Adds New Zepbound Vial Doses to the Mix

Image Credit: Adobe Stock Images/TadaImages.com Eli Lilly and Company is unveiling its new 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, which will be available for $499 per month using its new Zepbound Self Pay Journey Program.1 The prices of the 2.5 mg and 5 mg vials—introduced last summer2—have also been lowered to $349 and $499 […]

Continue Reading

A Side Effect Cascade

In a video interview with Pharma Commerce, Tom Dorsett, CEO, RazorMetrics, describes how polypharmacy refers to the use of five or more medications by an individual, and it is becoming an increasingly prominent issue in the United States. Polypharmacy has been recognized for years but is growing more significant, especially within Medicaid, Medicare, and large […]

Continue Reading

Selardsi Launches in the US Market

Image Credit: Adobe Stock Images/Oporty786.com Selarsdi (ustekinumab-aekn) an injection for the treatment of psoriatic arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, pediatric plaque psoriasis, and pediatric psoriatic arthritis that is also a biosimilar to Stelara (ustekinumab), is officially available in the United States.1 This represents under second biosimilar available in the US market under the Teva […]

Continue Reading

Understanding Polypharmacy

In a video interview with Pharma Commerce, Tom Dorsett, CEO, RazorMetrics, describes how polypharmacy refers to the use of five or more medications by an individual, and it is becoming an increasingly prominent issue in the United States. Polypharmacy has been recognized for years but is growing more significant, especially within Medicaid, Medicare, and large […]

Continue Reading

PharmExec’s 20th Annual 2025 Pipeline Report, Patient Journey and the Role of the Pharmacist & more

2025 Pipeline Report: The Edge of Greatness? The biopharmaceutical industry has long been at the forefront of innovation. From the rise of precision medicine, to artificial intelligence technologies accelerating drug development, to the advent of small-molecule drugs, recent revolutions in pharmaceuticals are delivering better results for patients and more options for drug manufacturers. Now, emerging […]

Continue Reading

Global Launch Strategies in the Current Political Climate, Pharmacists Help Navigate Vaccine Schedules & more

Global Launch Strategies in the Current Political Climate James Foster, CEO and co-founder of Virax Biolabs, discusses how global launches are being impacted by changing geopolitical conditions. Pharmacists Help Patients Navigate Vaccine Schedules Many patients may struggle to understand the complex immunization schedules compiled by the CDC. How AI Can Protect Vital Pipelines and Cables […]

Continue Reading

Challenges in Developing T Cell Engagers, Vietnam War Vets Are Still Battling PTSD, Along With Chronic Illnesses & more

Challenges in Developing T Cell Engagers Ian Chan, CEO of Abpro, discusses the advantages of their DiversImmune and MultiMab platforms for antibody discovery and engineering. Abpro’s platform can create novel antibodies at industry-leading speeds, which are then reassembled into custom configurations for therapeutic purposes. They have developed bispecific antibodies, particularly T cell engagers for oncology, […]

Continue Reading

The Role of Electronic Labeling in Sustainable Practices

In a video interview with Pharma Commerce, Laura Johnson, senior director of sales, life sciences, Loftware, discusses how supply chain collaboration is becoming increasingly important, particularly in the life sciences and pharmaceutical sectors. According to Johnson, the adoption of cloud-enabled collaborative supply chains is crucial for improving real-time data sharing. This enhances visibility and coordination […]

Continue Reading